ESC 365 - The influence of blinding and un-blinding on statin related adverse events (AEs): new evidence from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

ESC Premium Access

The influence of blinding and un-blinding on statin related adverse events (AEs): new evidence from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

Session: Clinical Trial Update Prevention

Topic: Epidemiology, lipids

Speaker: Associate Professor A. Gupta (London, GB)

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Associate Professor Ajay Gupta

Queen Mary University of London, London (United Kingdom of Great Britain & Northern Ireland)

2 presentations

0 follower

5 more presentations in this session

Primary prevention of patients with high LDL-cholesterol levels greater than 4.9 mmol/l: analysis from the WOSCOPS trial

Speaker: Doctor A. Vallejo-Vaz (Seville, ES)

Lipid Levels and CV Outcome with CETP Inhibition by Evacetrapib in the ACCELERATE Trial

Speaker: Professor A. Lincoff (Cleveland, US)

The Benefit of Adding Ezetimibe to Statin Therapy in Patients With or Without prior Coronary Artery Bypass Graft surgery in the IMPROVE-IT Trial

Speaker: Professor A. Eisen (Petah Tikva, IL)

First-in-man study of a pacemaker-mediated programmable hypertension control therapy

Speaker: Professor P. Neuzil (Prague, CZ)

The relationship between severe hypoglycaemic events and cardiovascular outcomes is bidirectional: novel results from TECOS

Speaker: Professor E. Standl (Munich, DE)

Access the full session

Clinical Trial Update Prevention

Speakers: Associate Professor A. Gupta, Doctor A. Vallejo-Vaz, Professor A. Lincoff, Professor A. Eisen, Professor P. Neuzil...

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources